“Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval

Background The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experienc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Annals of thoracic surgery 2008-11, Vol.86 (5), p.1530-1538
Hauptverfasser: Hughes, G. Chad, MD, Daneshmand, Mani A., MD, Swaminathan, Madhav, MD, Nienaber, Jeffrey J., MD, Bush, Errol L., MD, Husain, Aatif H., MD, Wolfe, Walter G., MD, McCann, Richard L., MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1538
container_issue 5
container_start_page 1530
container_title The Annals of thoracic surgery
container_volume 86
creator Hughes, G. Chad, MD
Daneshmand, Mani A., MD
Swaminathan, Madhav, MD
Nienaber, Jeffrey J., MD
Bush, Errol L., MD
Husain, Aatif H., MD
Wolfe, Walter G., MD
McCann, Richard L., MD
description Background The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experience with the TAG device for the 2 years post-approval to better characterize “real world” use and results outside the clinical trial setting. Methods Between March 23, 2005, and March 23, 2007, n = 91 thoracic endograft procedures were performed at our institution. Of these, n = 83 (91%) utilized the TAG device and form the basis of this report. Indications for endovascular repair were: fusiform or saccular aneurysm (n = 43; 52%), acute or chronic dissection (n = 30; 36%), acute or chronic traumatic transection (n = 7; 8%), and false aneurysm after prior aortic surgery (n = 3; 4%). A “hybrid” approach involving carotid-carotid bypass (n = 2), stage I elephant trunk procedure (n = 3), aortic arch debranching (n = 7), or complete visceral debranching (n = 5) was required in 20% of patients to create an adequate landing zone. Results Primary technical success rate was 98.8% (n = 82/83). Thirty-day rates of mortality and permanent stroke were both 3.6% (n = 3 each). Permanent paraparesis/paraplegia rate was 2.4% (n = 2). The 30-day rate of vascular or device-related complications requiring additional endovascular or open procedures was 7.2% (n = 6). During a mean duration of follow-up of 14 ± 8 months (range 0–28), there was one late death from aneurysm rupture (1.2%) and one late conversion to open repair (1.2%). Conclusions “Real world” utilization of the TAG device includes high rates of off-label use (nearly 50%) and “hybrid” techniques (20%) for the treatment of multiple pathologic entities of the thoracic and thoracoabdominal aorta. Regardless, short to mid-term results appear promising. Longer follow-up is needed to determine the durability of this approach.
doi_str_mv 10.1016/j.athoracsur.2008.07.089
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69858468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0003497508015932</els_id><sourcerecordid>69858468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-d8af66492ff19c43541caaec40cf8fb822801768378d2f6f1f3854fa7d9e02073</originalsourceid><addsrcrecordid>eNqNkc9q3DAQxkVpSLabvELRqTe7kizZcg8FN3-2hUAg2RByEoo8ymrrtTaSvZBbHqR9uTxJtd2FQE89DRp9833MbxDClOSU0PLzMtfDwgdt4hhyRojMSZUTWb9DEyoEy0om6vdoQggpMl5X4gh9iHGZnix9H6IjWpPU5nyCFq8vv65Bd_jOh659ffmN53-NncHnfesfg7aD6x-_4GuIYzdEfOeGBR4WgGc-AJ43M3wGG2cAM3wPOkTc2AECvs1vcnxx1uBmvQ5-o7tjdGB1F-FkX6fo9uJ8fvo9u7ya_ThtLjMjaDFkrdS2LHnNrKW14YXg1GgNhhNjpX2QjElCq1IWlWyZLS21hRTc6qqtgTBSFVP0aeebYp9GiINauWig63QPfoyqrKWQPBlMkdwJTfAxBrBqHdxKh2dFidpSVkv1RlltKStSqUQ5jX7cZ4wPK2jfBvdYk-DbTgBp042DoKJx0BtoXQAzqNa7_0n5-o-J6VzvjO5-wjPEpR9Dn0gqqiJTRN1sr709NkmERF2w4g-ce6hl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69858468</pqid></control><display><type>article</type><title>“Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Hughes, G. Chad, MD ; Daneshmand, Mani A., MD ; Swaminathan, Madhav, MD ; Nienaber, Jeffrey J., MD ; Bush, Errol L., MD ; Husain, Aatif H., MD ; Wolfe, Walter G., MD ; McCann, Richard L., MD</creator><creatorcontrib>Hughes, G. Chad, MD ; Daneshmand, Mani A., MD ; Swaminathan, Madhav, MD ; Nienaber, Jeffrey J., MD ; Bush, Errol L., MD ; Husain, Aatif H., MD ; Wolfe, Walter G., MD ; McCann, Richard L., MD</creatorcontrib><description>Background The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experience with the TAG device for the 2 years post-approval to better characterize “real world” use and results outside the clinical trial setting. Methods Between March 23, 2005, and March 23, 2007, n = 91 thoracic endograft procedures were performed at our institution. Of these, n = 83 (91%) utilized the TAG device and form the basis of this report. Indications for endovascular repair were: fusiform or saccular aneurysm (n = 43; 52%), acute or chronic dissection (n = 30; 36%), acute or chronic traumatic transection (n = 7; 8%), and false aneurysm after prior aortic surgery (n = 3; 4%). A “hybrid” approach involving carotid-carotid bypass (n = 2), stage I elephant trunk procedure (n = 3), aortic arch debranching (n = 7), or complete visceral debranching (n = 5) was required in 20% of patients to create an adequate landing zone. Results Primary technical success rate was 98.8% (n = 82/83). Thirty-day rates of mortality and permanent stroke were both 3.6% (n = 3 each). Permanent paraparesis/paraplegia rate was 2.4% (n = 2). The 30-day rate of vascular or device-related complications requiring additional endovascular or open procedures was 7.2% (n = 6). During a mean duration of follow-up of 14 ± 8 months (range 0–28), there was one late death from aneurysm rupture (1.2%) and one late conversion to open repair (1.2%). Conclusions “Real world” utilization of the TAG device includes high rates of off-label use (nearly 50%) and “hybrid” techniques (20%) for the treatment of multiple pathologic entities of the thoracic and thoracoabdominal aorta. Regardless, short to mid-term results appear promising. Longer follow-up is needed to determine the durability of this approach.</description><identifier>ISSN: 0003-4975</identifier><identifier>EISSN: 1552-6259</identifier><identifier>DOI: 10.1016/j.athoracsur.2008.07.089</identifier><identifier>PMID: 19049744</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Aneurysm, Dissecting - surgery ; Aorta, Thoracic - diagnostic imaging ; Aorta, Thoracic - surgery ; Aortic Aneurysm, Thoracic - mortality ; Aortic Aneurysm, Thoracic - surgery ; Blood Vessel Prosthesis - adverse effects ; Cardiothoracic Surgery ; Female ; Follow-Up Studies ; Humans ; Image Processing, Computer-Assisted ; Male ; Middle Aged ; Paraparesis - etiology ; Polytetrafluoroethylene ; Prosthesis Design - instrumentation ; Reoperation ; Stroke - etiology ; Surgery ; Survival Rate ; Tomography, X-Ray Computed ; Treatment Outcome ; United States ; United States Food and Drug Administration</subject><ispartof>The Annals of thoracic surgery, 2008-11, Vol.86 (5), p.1530-1538</ispartof><rights>The Society of Thoracic Surgeons</rights><rights>2008 The Society of Thoracic Surgeons</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-d8af66492ff19c43541caaec40cf8fb822801768378d2f6f1f3854fa7d9e02073</citedby><cites>FETCH-LOGICAL-c513t-d8af66492ff19c43541caaec40cf8fb822801768378d2f6f1f3854fa7d9e02073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19049744$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hughes, G. Chad, MD</creatorcontrib><creatorcontrib>Daneshmand, Mani A., MD</creatorcontrib><creatorcontrib>Swaminathan, Madhav, MD</creatorcontrib><creatorcontrib>Nienaber, Jeffrey J., MD</creatorcontrib><creatorcontrib>Bush, Errol L., MD</creatorcontrib><creatorcontrib>Husain, Aatif H., MD</creatorcontrib><creatorcontrib>Wolfe, Walter G., MD</creatorcontrib><creatorcontrib>McCann, Richard L., MD</creatorcontrib><title>“Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval</title><title>The Annals of thoracic surgery</title><addtitle>Ann Thorac Surg</addtitle><description>Background The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experience with the TAG device for the 2 years post-approval to better characterize “real world” use and results outside the clinical trial setting. Methods Between March 23, 2005, and March 23, 2007, n = 91 thoracic endograft procedures were performed at our institution. Of these, n = 83 (91%) utilized the TAG device and form the basis of this report. Indications for endovascular repair were: fusiform or saccular aneurysm (n = 43; 52%), acute or chronic dissection (n = 30; 36%), acute or chronic traumatic transection (n = 7; 8%), and false aneurysm after prior aortic surgery (n = 3; 4%). A “hybrid” approach involving carotid-carotid bypass (n = 2), stage I elephant trunk procedure (n = 3), aortic arch debranching (n = 7), or complete visceral debranching (n = 5) was required in 20% of patients to create an adequate landing zone. Results Primary technical success rate was 98.8% (n = 82/83). Thirty-day rates of mortality and permanent stroke were both 3.6% (n = 3 each). Permanent paraparesis/paraplegia rate was 2.4% (n = 2). The 30-day rate of vascular or device-related complications requiring additional endovascular or open procedures was 7.2% (n = 6). During a mean duration of follow-up of 14 ± 8 months (range 0–28), there was one late death from aneurysm rupture (1.2%) and one late conversion to open repair (1.2%). Conclusions “Real world” utilization of the TAG device includes high rates of off-label use (nearly 50%) and “hybrid” techniques (20%) for the treatment of multiple pathologic entities of the thoracic and thoracoabdominal aorta. Regardless, short to mid-term results appear promising. Longer follow-up is needed to determine the durability of this approach.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aneurysm, Dissecting - surgery</subject><subject>Aorta, Thoracic - diagnostic imaging</subject><subject>Aorta, Thoracic - surgery</subject><subject>Aortic Aneurysm, Thoracic - mortality</subject><subject>Aortic Aneurysm, Thoracic - surgery</subject><subject>Blood Vessel Prosthesis - adverse effects</subject><subject>Cardiothoracic Surgery</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Image Processing, Computer-Assisted</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Paraparesis - etiology</subject><subject>Polytetrafluoroethylene</subject><subject>Prosthesis Design - instrumentation</subject><subject>Reoperation</subject><subject>Stroke - etiology</subject><subject>Surgery</subject><subject>Survival Rate</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0003-4975</issn><issn>1552-6259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9q3DAQxkVpSLabvELRqTe7kizZcg8FN3-2hUAg2RByEoo8ymrrtTaSvZBbHqR9uTxJtd2FQE89DRp9833MbxDClOSU0PLzMtfDwgdt4hhyRojMSZUTWb9DEyoEy0om6vdoQggpMl5X4gh9iHGZnix9H6IjWpPU5nyCFq8vv65Bd_jOh659ffmN53-NncHnfesfg7aD6x-_4GuIYzdEfOeGBR4WgGc-AJ43M3wGG2cAM3wPOkTc2AECvs1vcnxx1uBmvQ5-o7tjdGB1F-FkX6fo9uJ8fvo9u7ya_ThtLjMjaDFkrdS2LHnNrKW14YXg1GgNhhNjpX2QjElCq1IWlWyZLS21hRTc6qqtgTBSFVP0aeebYp9GiINauWig63QPfoyqrKWQPBlMkdwJTfAxBrBqHdxKh2dFidpSVkv1RlltKStSqUQ5jX7cZ4wPK2jfBvdYk-DbTgBp042DoKJx0BtoXQAzqNa7_0n5-o-J6VzvjO5-wjPEpR9Dn0gqqiJTRN1sr709NkmERF2w4g-ce6hl</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>Hughes, G. Chad, MD</creator><creator>Daneshmand, Mani A., MD</creator><creator>Swaminathan, Madhav, MD</creator><creator>Nienaber, Jeffrey J., MD</creator><creator>Bush, Errol L., MD</creator><creator>Husain, Aatif H., MD</creator><creator>Wolfe, Walter G., MD</creator><creator>McCann, Richard L., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20081101</creationdate><title>“Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval</title><author>Hughes, G. Chad, MD ; Daneshmand, Mani A., MD ; Swaminathan, Madhav, MD ; Nienaber, Jeffrey J., MD ; Bush, Errol L., MD ; Husain, Aatif H., MD ; Wolfe, Walter G., MD ; McCann, Richard L., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-d8af66492ff19c43541caaec40cf8fb822801768378d2f6f1f3854fa7d9e02073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aneurysm, Dissecting - surgery</topic><topic>Aorta, Thoracic - diagnostic imaging</topic><topic>Aorta, Thoracic - surgery</topic><topic>Aortic Aneurysm, Thoracic - mortality</topic><topic>Aortic Aneurysm, Thoracic - surgery</topic><topic>Blood Vessel Prosthesis - adverse effects</topic><topic>Cardiothoracic Surgery</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Image Processing, Computer-Assisted</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Paraparesis - etiology</topic><topic>Polytetrafluoroethylene</topic><topic>Prosthesis Design - instrumentation</topic><topic>Reoperation</topic><topic>Stroke - etiology</topic><topic>Surgery</topic><topic>Survival Rate</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hughes, G. Chad, MD</creatorcontrib><creatorcontrib>Daneshmand, Mani A., MD</creatorcontrib><creatorcontrib>Swaminathan, Madhav, MD</creatorcontrib><creatorcontrib>Nienaber, Jeffrey J., MD</creatorcontrib><creatorcontrib>Bush, Errol L., MD</creatorcontrib><creatorcontrib>Husain, Aatif H., MD</creatorcontrib><creatorcontrib>Wolfe, Walter G., MD</creatorcontrib><creatorcontrib>McCann, Richard L., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of thoracic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hughes, G. Chad, MD</au><au>Daneshmand, Mani A., MD</au><au>Swaminathan, Madhav, MD</au><au>Nienaber, Jeffrey J., MD</au><au>Bush, Errol L., MD</au><au>Husain, Aatif H., MD</au><au>Wolfe, Walter G., MD</au><au>McCann, Richard L., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>“Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval</atitle><jtitle>The Annals of thoracic surgery</jtitle><addtitle>Ann Thorac Surg</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>86</volume><issue>5</issue><spage>1530</spage><epage>1538</epage><pages>1530-1538</pages><issn>0003-4975</issn><eissn>1552-6259</eissn><abstract>Background The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experience with the TAG device for the 2 years post-approval to better characterize “real world” use and results outside the clinical trial setting. Methods Between March 23, 2005, and March 23, 2007, n = 91 thoracic endograft procedures were performed at our institution. Of these, n = 83 (91%) utilized the TAG device and form the basis of this report. Indications for endovascular repair were: fusiform or saccular aneurysm (n = 43; 52%), acute or chronic dissection (n = 30; 36%), acute or chronic traumatic transection (n = 7; 8%), and false aneurysm after prior aortic surgery (n = 3; 4%). A “hybrid” approach involving carotid-carotid bypass (n = 2), stage I elephant trunk procedure (n = 3), aortic arch debranching (n = 7), or complete visceral debranching (n = 5) was required in 20% of patients to create an adequate landing zone. Results Primary technical success rate was 98.8% (n = 82/83). Thirty-day rates of mortality and permanent stroke were both 3.6% (n = 3 each). Permanent paraparesis/paraplegia rate was 2.4% (n = 2). The 30-day rate of vascular or device-related complications requiring additional endovascular or open procedures was 7.2% (n = 6). During a mean duration of follow-up of 14 ± 8 months (range 0–28), there was one late death from aneurysm rupture (1.2%) and one late conversion to open repair (1.2%). Conclusions “Real world” utilization of the TAG device includes high rates of off-label use (nearly 50%) and “hybrid” techniques (20%) for the treatment of multiple pathologic entities of the thoracic and thoracoabdominal aorta. Regardless, short to mid-term results appear promising. Longer follow-up is needed to determine the durability of this approach.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>19049744</pmid><doi>10.1016/j.athoracsur.2008.07.089</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0003-4975
ispartof The Annals of thoracic surgery, 2008-11, Vol.86 (5), p.1530-1538
issn 0003-4975
1552-6259
language eng
recordid cdi_proquest_miscellaneous_69858468
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Adult
Aged
Aged, 80 and over
Aneurysm, Dissecting - surgery
Aorta, Thoracic - diagnostic imaging
Aorta, Thoracic - surgery
Aortic Aneurysm, Thoracic - mortality
Aortic Aneurysm, Thoracic - surgery
Blood Vessel Prosthesis - adverse effects
Cardiothoracic Surgery
Female
Follow-Up Studies
Humans
Image Processing, Computer-Assisted
Male
Middle Aged
Paraparesis - etiology
Polytetrafluoroethylene
Prosthesis Design - instrumentation
Reoperation
Stroke - etiology
Surgery
Survival Rate
Tomography, X-Ray Computed
Treatment Outcome
United States
United States Food and Drug Administration
title “Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T15%3A34%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%E2%80%9CReal%20World%E2%80%9D%20Thoracic%20Endografting:%20Results%20With%20the%20Gore%20TAG%20Device%202%20Years%20After%20U.S.%20FDA%20Approval&rft.jtitle=The%20Annals%20of%20thoracic%20surgery&rft.au=Hughes,%20G.%20Chad,%20MD&rft.date=2008-11-01&rft.volume=86&rft.issue=5&rft.spage=1530&rft.epage=1538&rft.pages=1530-1538&rft.issn=0003-4975&rft.eissn=1552-6259&rft_id=info:doi/10.1016/j.athoracsur.2008.07.089&rft_dat=%3Cproquest_cross%3E69858468%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69858468&rft_id=info:pmid/19049744&rft_els_id=S0003497508015932&rfr_iscdi=true